4886 Aska Pharm Holdings
- Japan Guru
- May 15, 2025
- 1 min read
Close relationship with Takeda. Strong in gynecology field. Focus on increasing the ratio of original drugs. Aska Pharmaceutical will become a holding company in spring 2021.
top of page
No.1 English-language social media platform for Japanese stocks
Powered by Japan Guru
4 Comments
bottom of page
severe rebuke by the activists to the poison pill and the letter they received telling them not to buy any more shares
this retail investor sympathizes with the activists and notes that Aska has unrealized gain on its real estate:
https://x.com/26ooo/status/1942544508924879358
The management, together with biz partner like Takeda Pharm and banks, appears to control some 23% <
Everyone's happy if Takeda TOBs. And maybe that's what the activists are going for
A group of activists acting in concert together hold 21.635%, the largest voting block. They are: Nippon Active Value Fund, Dalton Investments and Rising Sun Management.
Apparently, the Aska management recently sent these activists a letter saying "please stop buying our shares any more because you guys are a fund that must exit and would thereby cause our stock price to fall to the detriment of all the other shareholders"
This management either lack financial literacy or engaged bad advisors, or both
With rev rising at least since 2022, earning 4 ~ 5 bil yen in net profit consistently and Prime-section listed, the activists have an upper hand here
at 2357 yen/share, 67.8 bil yen mkt cap vs 35 bil yen net cash
12.86x per / 1.02x pbr / 2.33% dividend